Caid Katherine, Tate Megan, Yousuf Shahwar, Jones Lillian, Pesek Robert D, Jefferson Akilah A, Perry Tamara T, Liu Daniel, Turner Grace, Ingold Ashton, Hartzell Susanna, Boyanton Bobby L, Cobb Kim, Long Haley, House Suzanne, Frederick Dana, Frenner Rachel A, Hathorn Erin, Jin Jing, Stewart Scott, Kennedy Joshua L
Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Ark.
Arkansas Children's Research Institute, Little Rock, Ark.
J Allergy Clin Immunol Glob. 2024 Sep 11;3(4):100340. doi: 10.1016/j.jacig.2024.100340. eCollection 2024 Nov.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in March 2020 led to the implementation of nonpharmaceutical interventions (NPIs) to curb its spread. Studies have shown that adult asthma exacerbations and viral infections decreased during NPI use. However, few studies have shown the effects of NPIs on pediatric asthma exacerbations and infections during and after the pandemic.
This study aimed to understand the impact of NPIs on asthma exacerbations and viral respiratory infections in pediatric patients at our institution from March 2018 to December 2022.
The medical record numbers of children with asthma exacerbations seen at our institution between March 2018 and December 2022 were analyzed. Subjects were categorized on the basis of timing of their exacerbation in relation to NPI enforcement. We used the results from clinical testing with the BioFire Respiratory Panel (BRP) to detect up to 22 respiratory pathogens and then correlated these results with asthma exacerbation severity.
There were 5,758 asthma exacerbations recorded, with a 50% decline in average weekly exacerbations during NPI enforcement. Of the 70,682 BRP tests performed, 87% returned a positive result for at least 1 pathogen. Several viruses (respiratory syncytial virus, parainfluenza, and influenza) had a decrease in positivity rate with NPIs, whereas rhinovirus/enterovirus positivity rates were unchanged throughout the pandemic. Asthma exacerbations with a positive BRP result required higher clinical levels of care during the admission.
NPIs were associated with significantly reduced numbers of asthma exacerbations and respiratory viral infections. The post-NPI period saw a return to prepandemic levels of asthma exacerbations and an unusual surge in respiratory syncytial virus infections, emphasizing the need for continuous monitoring and adaptive strategies in the postpandemic landscape.
2020年3月严重急性呼吸综合征冠状病毒2(SARS-CoV-2)出现后,为遏制其传播实施了非药物干预措施(NPIs)。研究表明,在使用NPIs期间,成人哮喘加重和病毒感染有所减少。然而,很少有研究表明NPIs在大流行期间及之后对儿童哮喘加重和感染的影响。
本研究旨在了解2018年3月至2022年12月期间NPIs对本机构儿科患者哮喘加重和病毒性呼吸道感染的影响。
分析了2018年3月至2022年12月期间在本机构就诊的哮喘加重儿童的病历号。根据其加重时间与NPI实施的关系对受试者进行分类。我们使用BioFire呼吸检测板(BRP)的临床检测结果来检测多达22种呼吸道病原体,然后将这些结果与哮喘加重的严重程度相关联。
共记录了5758次哮喘加重,在实施NPI期间平均每周加重次数下降了50%。在进行的70682次BRP检测中,87%的检测结果显示至少有一种病原体呈阳性。几种病毒(呼吸道合胞病毒、副流感病毒和流感病毒)的阳性率在实施NPIs后有所下降,而鼻病毒/肠道病毒的阳性率在整个大流行期间保持不变。BRP检测结果呈阳性的哮喘加重患者在入院期间需要更高水平的临床护理。
NPIs与哮喘加重和呼吸道病毒感染数量的显著减少有关。NPI实施后,哮喘加重情况恢复到疫情前水平,呼吸道合胞病毒感染出现异常激增,这凸显了在疫情后环境中持续监测和采取适应性策略的必要性。